Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses-Reference-Cited by-同舟云学术

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

Published:2021-01-11 Issue:4 Volume:96 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Brown Jennifer R.¹²,Walker Sarah R.¹²,Heppler Lisa N.¹,Tyekucheva Svitlana³,Nelson Erik A.¹²,Klitgaard Josephine¹,Nicolais Maria¹,Kroll Yasmin¹,Xiang Michael¹,Yeh Jennifer E.¹,Chaudhury Mousumi¹,Giaccone Zachary T.¹,Fernandes Stacey M.¹,Jacobsen Eric D.¹²,Fisher David C.¹²,Freedman Arnold S.¹²^ORCID,Davids Matthew S.¹²,Supko Jeffrey G.⁴,Wu Catherine¹²,Frank David A.¹²^ORCID

Affiliation:

1. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

2. Departments of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

3. Department of Data Sciences Dana‐Farber Cancer Institute Boston Massachusetts USA

4. Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA

Funder

Lymphoma Research Foundation

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26084

Reference6 articles.

1. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.

2. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells

3. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

4. A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation

5. Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of IL-22 in cancer;Medical Oncology;2024-09-05

2. C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration;Journal of Translational Medicine;2024-08-22

3. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation;Cancers;2024-03-31

4. Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations;Bioorganic Chemistry;2024-02

5. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics;Cancers;2024-01-24